Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 233 across all filing types
Latest filing 2026-05-29 Proxy Solicitation & In…
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT Therapeutics - Notice for Annual General Meeting 2026 - Attachment: EXACT Therapeutics AGM 2026 Notice.pdf
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal NOTICE OF ANNUAL GENERAL MEETING (AGM) containing the agenda, proposals to shareholders, board and committee elections, remuneration items, and authorizations for share capital increases. It is sent to shareholders to inform and solicit votes at the upcoming AGM. Therefore it fits the Proxy Solicitation & Information Statement category rather than an actual report or vote result.
2026-05-29 Norwegian Bokmål
EXACT Therapeutics - Notice for Annual General Meeting 2026
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a formal notice convening the Annual General Meeting, sent to shareholders with the meeting date, time, and instruction that the formal notice (proxy material) is attached and available on the company website. This aligns with the Proxy Solicitation & Information Statement category (materials sent to shareholders to provide information and request votes). It is not the full annual report or earnings release, nor merely a regulatory filing or share issue notice. Therefore, it should be classified as PSI.
2026-05-29 English
EXACT Therapeutics: Strategic intent to delist the company’s shares from listing on Euronext Growth, Oslo
Delisting Announcement Classification · 90% confidence The document is a corporate announcement detailing the Board’s proposal to delist the company’s shares from Euronext Growth Oslo, describing the rationale, shareholder composition, and next steps for delisting. This fits the ‘Delisting Announcement’ category.
2026-05-29 English
EXACT Therapeutics - Annual Report 2025 - Attachment: 2025 EXACT Therapeutics AS Annual Report.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2025' and contains comprehensive sections including a Letter from the CEO, Board of Directors' Report, Financial Review, and detailed financial statements (Operating expenses, Financial position, Cash flow). It covers the company's activities, strategy, and financial performance for the full fiscal year 2025, fitting the definition of an Annual Report (10-K). FY 2025
2026-04-09 English
EXACT Therapeutics - Annual Report 2025
Report Publication Announcement Classification · 92% confidence The document is a brief notice stating “Please find enclosed the 2025 Annual Report” without containing the report’s financials or detailed management commentary. At under 1,000 characters and serving solely to publish or attach the report, it fits the Report Publication Announcement category rather than the full Annual Report itself.
2026-04-09 English
EXACT Therapeutics AS: Share capital increase registered
Share Issue/Capital Change Classification · 95% confidence The document is a short stock exchange announcement stating that the company’s share capital increase—resulting from the issuance of new shares upon exercise of warrants—has been registered with the Norwegian Register of Business Enterprises. This is clearly an announcement of a capital change (new share issue) rather than a full report or other regulatory filing. Therefore, the correct classification is Share Issue/Capital Change (SHA).
2026-03-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.